AXQ Capital LP Raises Stock Position in Kura Oncology, Inc. $KURA

AXQ Capital LP boosted its stake in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 74.2% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 45,472 shares of the company’s stock after acquiring an additional 19,369 shares during the period. AXQ Capital LP owned about 0.05% of Kura Oncology worth $262,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. State of Wyoming purchased a new stake in shares of Kura Oncology during the first quarter worth about $48,000. Pallas Capital Advisors LLC boosted its holdings in Kura Oncology by 32.2% in the 2nd quarter. Pallas Capital Advisors LLC now owns 13,304 shares of the company’s stock worth $77,000 after buying an additional 3,241 shares during the last quarter. Magnetar Financial LLC acquired a new stake in Kura Oncology in the 1st quarter worth about $79,000. E Fund Management Co. Ltd. increased its stake in Kura Oncology by 18.9% during the 1st quarter. E Fund Management Co. Ltd. now owns 12,252 shares of the company’s stock worth $81,000 after buying an additional 1,951 shares in the last quarter. Finally, Teacher Retirement System of Texas raised its holdings in shares of Kura Oncology by 29.3% during the second quarter. Teacher Retirement System of Texas now owns 16,235 shares of the company’s stock valued at $94,000 after acquiring an additional 3,683 shares during the last quarter.

Analysts Set New Price Targets

A number of analysts have recently issued reports on KURA shares. UBS Group lifted their price target on Kura Oncology from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, November 14th. Wedbush reaffirmed an “outperform” rating and set a $38.00 target price (up previously from $36.00) on shares of Kura Oncology in a research note on Friday, November 14th. Wall Street Zen upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a research report on Sunday, August 17th. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Kura Oncology in a research note on Friday, November 14th. Finally, Zacks Research upgraded shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a research report on Wednesday, November 5th. Seven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Kura Oncology currently has an average rating of “Moderate Buy” and an average target price of $26.57.

Kura Oncology Trading Up 5.0%

Shares of Kura Oncology stock opened at $11.73 on Tuesday. The stock has a 50 day moving average of $9.82 and a 200 day moving average of $7.70. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.12 and a current ratio of 5.12. The firm has a market capitalization of $1.02 billion, a price-to-earnings ratio of -4.73 and a beta of 0.34. Kura Oncology, Inc. has a fifty-two week low of $5.41 and a fifty-two week high of $12.49.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Tuesday, November 4th. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). The business had revenue of $20.75 million during the quarter, compared to analysts’ expectations of $17.48 million. Kura Oncology had a negative net margin of 208.48% and a negative return on equity of 65.42%. As a group, research analysts predict that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Insider Buying and Selling

In other Kura Oncology news, insider Teresa Brophy Bair sold 8,805 shares of the company’s stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $8.94, for a total value of $78,716.70. Following the transaction, the insider owned 148,043 shares of the company’s stock, valued at $1,323,504.42. This represents a 5.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Brian T. Powl sold 8,891 shares of the stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $8.94, for a total transaction of $79,485.54. Following the transaction, the insider directly owned 99,676 shares of the company’s stock, valued at approximately $891,103.44. This trade represents a 8.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 122,675 shares of company stock valued at $1,196,657 over the last three months. Company insiders own 6.40% of the company’s stock.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.